AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3291558 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (mean dose 86 mg/day)
Number of subjects: 23
Study 3291558 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (mean dose 305 mg/day)
Number of subjects: 23
Study 3291558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30595565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (50,000 IU weekly) with calcitriol (0.25 mg/d) for 3 months
Number of subjects: 40
Study 30595565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27488472 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg + standard of care (SoC)
Number of subjects: 834
Study 27488472 — intervention group
Group type: COMPARATOR
Intervention: placebo + standard of care (SoC)
Number of subjects: 834
Study 27488472 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg + steroids only
Number of subjects: 834
Study 27488472 — intervention group
Group type: COMPARATOR
Intervention: placebo + steroids only
Number of subjects: 834
Study 27488472 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg + steroids + AM
Number of subjects: 834
Study 27488472 — intervention group
Group type: COMPARATOR
Intervention: placebo + steroids + AM
Number of subjects: 834
Study 24643443 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (distribution and free access to educational study materials)
Number of subjects: 0
Study 21962976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal tDCS (1.5 mA for 20 minutes)
Number of subjects: 17
Study 21962976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioccipital tDCS (1.5 mA for 20 minutes)
Number of subjects: 17
Study 21962976 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 17
Study 20021997 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (n = 111)
Number of subjects: 217
Study 20021997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 106)
Number of subjects: 217
Study 17932136 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP infusion (80 mug (kg body mass)(‐1) min(‐1))
Number of subjects: 8
Study 17932136 — intervention group
Group type: COMPARATOR
Intervention: Control (no ATP infusion)
Number of subjects: 8
Study 16273792 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Activity Score (DAS)
Number of subjects: 0
Study 16273792 — intervention group
Group type: EXPERIMENTAL
Intervention: EULAR response criteria
Number of subjects: 0
Study 12108801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 228
Study 12108801 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 228
Study 9475565 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate double-strength 84 microg (5 puffs BID)
Number of subjects: 64
Study 9475565 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate regular-strength 42 microg (10 puffs BID)
Number of subjects: 64
Study 9475565 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg once a day
Number of subjects: 64
Study 9475565 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 64
Study 8523629 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone, glutamine, and a modified high-carbohydrate, high-fiber diet
Number of subjects: 10
Study 8523629 — intervention group
Group type: COMPARATOR
Intervention: Modified diet alone
Number of subjects: 10
Study 2229457 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 99
Study 2229457 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 99
Study 2229457 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 99
Study 2229457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 589075 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy
Number of subjects: 3
Study 589075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal examination with sweeping of the fetal membranes
Number of subjects: 3
Study 589075 — intervention group
Group type: COMPARATOR
Intervention: Vaginal examination without sweeping of the membranes
Number of subjects: 3
Study 30687994 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein 100 mg/day
Number of subjects: 69
Study 30687994 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 69
Study 29668746 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 209
Study 29668746 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 209
Study 27102407 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace environmental dietary modification intervention
Number of subjects: 4
Study 27102407 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 4
Study 27102407 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of workplace environmental dietary modification and educational intervention
Number of subjects: 4
Study 27102407 — intervention group
Group type: COMPARATOR
Intervention: Control workplace
Number of subjects: 4
Study 25715572 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis (20 procedures, 20 minutes each)
Number of subjects: 60
Study 25715572 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic field (20 procedures, 30 minutes each)
Number of subjects: 60
Study 25715572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iontophoresis and magnetic field (20 procedures)
Number of subjects: 60
Study 25715572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 60
Study 21531481 — intervention group
Group type: EXPERIMENTAL
Intervention: HiDHA supplementation (1000 mg of tuna oil; comprising 252 mg DHA, 60 mg EPA and 10 mg vitamin E)
Number of subjects: 74
Study 21531481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mg soybean oil)
Number of subjects: 74
Study 21531481 — intervention group
Group type: EXPERIMENTAL
Intervention: HiDHA supplementation
Number of subjects: 74
Study 20679736 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 17
Study 20679736 — intervention group
Group type: COMPARATOR
Intervention: Non-ASV (control group)
Number of subjects: 17
Study 17711912 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise (PRE)
Number of subjects: 22
Study 16376751 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hemodialysis (H/D)
Number of subjects: 54
Study 16376751 — intervention group
Group type: COMPARATOR
Intervention: Normal LV systolic function (control group)
Number of subjects: 54
Study 16376751 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal LV systolic function
Number of subjects: 54
Study 12212785 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (estradiol)
Number of subjects: 0
Study 12212785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10030765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole plus L-dopa
Number of subjects: 30
Study 10030765 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 30
Study 7573879 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block using 0.125% bupivacaine with adrenaline
Number of subjects: 39
Study 7573879 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block using 0.125% bupivacaine with adrenaline + rectally administered diclofenac 1 mg.kg‐1
Number of subjects: 39
Study 2344682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg orally
Number of subjects: 30
Study 2344682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 88732 — intervention group
Group type: EXPERIMENTAL
Intervention: BACO
Number of subjects: 0
Study 88732 — intervention group
Group type: EXPERIMENTAL
Intervention: SAKK
Number of subjects: 0
Study 88732 — intervention group
Group type: EXPERIMENTAL
Intervention: BACO and SAKK
Number of subjects: 0
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in SEER cohort
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in SEER cohort after IPW adjustment
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in high-risk men in SEER cohort after IPW adjustment
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in VA cohort after IPW adjustment
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in RCT cohort after IPW adjustment
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in SEER cohort for other-cause mortality (OCM)
Number of subjects: 306100
Study 31120534 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race in RCT cohort for OCM
Number of subjects: 306100
Study 28531910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 0
Study 28531910 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial treatment (Control)
Number of subjects: 0
Study 25093677 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6
Study 25093677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 24709264 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01% gel
Number of subjects: 0
Study 24709264 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study 24709264 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg orally twice daily for 5 days (RESI-VAL)
Number of subjects: 0
Study 24709264 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (RESI-PLA)
Number of subjects: 0
Study 24709264 — intervention group
Group type: COMPARATOR
Intervention: Vehicle and oral placebo (VEH-PLA)
Number of subjects: 0
Study 22079954 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily enteral zinc, selenium, glutamine, and intravenous metoclopramide (n = 149)
Number of subjects: 293
Study 22079954 — intervention group
Group type: COMPARATOR
Intervention: Daily enteral whey protein (n = 144)
Number of subjects: 293
Study 19173752 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0
Study 19173752 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate NIV application to extubated patients at high risk for extubation failure
Number of subjects: 0
Study 19173752 — intervention group
Group type: COMPARATOR
Intervention: NIV in heterogeneous patient populations
Number of subjects: 0
Study 19173752 — intervention group
Group type: COMPARATOR
Intervention: NIV in case-control study
Number of subjects: 0
Study 17074511 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-flexion knee radiography
Number of subjects: 193
Study 17074511 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-flexion knee radiography with satisfactory MTP alignment
Number of subjects: 193
Study 17074511 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-flexion knee radiography with accurately reproduced IMD
Number of subjects: 193
Study 15178151 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐lactalbumin supplement combined with carbohydrates (AS)
Number of subjects: 18
Study 15178151 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrates only (PS)
Number of subjects: 18
Study 11771585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni‐Ti Pow‐R 0.04 ISO taper rotary files
Number of subjects: 30
Study 11771585 — intervention group
Group type: COMPARATOR
Intervention: Ni‐Ti ProFile 0.04 ISO taper rotary files
Number of subjects: 30
Study 10099033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril 30 mg + Indapamide 1.25 mg once daily for 24 weeks
Number of subjects: 28
Study 10099033 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril + Indapamide
Number of subjects: 28
Study 1552469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus metronidazole
Number of subjects: 23
Study 1552469 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metronidazole
Number of subjects: 23
Study 1552469 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 23
Study 1552469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2952046 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet 0.3% cream
Number of subjects: 51
Study 2952046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 30136644 — intervention group
Group type: COMPARATOR
Intervention: Information about local psychological services only (Control)
Number of subjects: 306
Study 30136644 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus regular symptom monitoring (every 6 days)
Number of subjects: 306
Study 30136644 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus open symptom monitoring (monitoring when they felt like it)
Number of subjects: 306
Study 29626267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation strategy with FiO2 1.0
Number of subjects: 50
Study 29626267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation strategy with EtCO2 40 mmHg
Number of subjects: 50
Study 29626267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at T6 (MAP back to baseline)
Number of subjects: 50
Study 29626267 — intervention group
Group type: COMPARATOR
Intervention: Control group with FiO2 0.4 and EtCO2 30 mmHg without PEEP
Number of subjects: 50
Study 27091076 — intervention group
Group type: EXPERIMENTAL
Intervention: D4-MEHP (50μg/kg bw)
Number of subjects: 4
Study 27091076 — intervention group
Group type: EXPERIMENTAL
Intervention: D4-MnBP (10μg/kg bw)
Number of subjects: 4
Study 24853311 — intervention group
Group type: COMPARATOR
Intervention: Adherence counseling intervention based on Lifesteps, an evidence-based HIV treatment adherence intervention; median number of sessions: 10.
Number of subjects: 1147
Study 22330696 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)) and carboplatin (AUC 6) followed by irradiation to the involved field (50.4 Gy pelvis ± 43.5 Gy paraaortic) ± brachytherapy
Number of subjects: 45
Study 20645945 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 ng.ml(‐1)
Number of subjects: 104
Study 20645945 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 ng.ml(‐1) remifentanil)
Number of subjects: 104
Study 20645945 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 ng.ml(‐1)
Number of subjects: 104
Study 17205281 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 12343
Study 17205281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 12343
Study 17205281 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 12343
Study 17205281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 24 or 32 mg
Number of subjects: 12343
Study 17205281 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron higher doses (24 or 32 mg)
Number of subjects: 12343
Study 16041629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 microg every 12 hours)
Number of subjects: 0
Study 16041629 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (200 microg every 12 hours) + Isosorbide dinitrate (5 mg single dose)
Number of subjects: 0
Study 11998910 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 2924
Study 11998910 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine
Number of subjects: 2924
Study 11998910 — intervention group
Group type: COMPARATOR
Intervention: DT vaccine
Number of subjects: 2924
Study 9808824 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted communications campaign utilizing radio and television advertisements and community outreach
Number of subjects: 14
Study 9808824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no targeted communications campaign)
Number of subjects: 14
Study 7579103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms/kg, propofol at 10 mg/kg/h, reduced to 1 microgram/kg/min after 4 min.
Number of subjects: 30
Study 7579103 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 75 micrograms/kg, propofol at 10 mg/kg/h, reduced to 2 micrograms/kg/min after 4 min.
Number of subjects: 30
Study 7579103 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Alfentanil 50 and 75 micrograms/kg)
Number of subjects: 30
Study 2135712 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden 2.5 mg
Number of subjects: 12
Study 2135712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.5 mg
Number of subjects: 12
Study 2135712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7001207 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3.3 mg daily)
Number of subjects: 54
Study 7001207 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.5 mg daily)
Number of subjects: 54
Study 7001207 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 54
Study 7001207 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 54
Study 7001207 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 54
Study 31543382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral group (n=30) using Trios Scanner, 3Shape
Number of subjects: 47
Study 31543382 — intervention group
Group type: COMPARATOR
Intervention: Extraoral group (n=30) using D900L Lab Scanner, 3Shape
Number of subjects: 47
Study 31374428 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 73
Study 31374428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 28292333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based counselling
Number of subjects: 0
Study 28292333 — intervention group
Group type: COMPARATOR
Intervention: Field clinics or home visits counselling
Number of subjects: 0
Study 28292333 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling in hospital admission wards
Number of subjects: 0
Study 28292333 — intervention group
Group type: COMPARATOR
Intervention: Information about risks and alternatives to PPIUD
Number of subjects: 0
Study 26275705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus cognitive‐coping therapy (pCCT)
Number of subjects: 215
Study 26275705 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy plus psychological support (PPS)
Number of subjects: 215
Study 23467363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (TES) to the posterior parietal cortex
Number of subjects: 0
Study 23467363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (TES) to the dorsolateral prefrontal cortex
Number of subjects: 0
Study 21303262 — intervention group
Group type: EXPERIMENTAL
Intervention: LGNC-07 (1,680 mg for 16 weeks)
Number of subjects: 91
Study 21303262 — intervention group
Group type: COMPARATOR
Intervention: LGNC-07 (single dose)
Number of subjects: 91
Study 19843667 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) ELISA (enhanced version, >or=6 pg/mL cut-point)
Number of subjects: 1781
Study 19843667 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) ELISA (original version, >or=8 pg/mL cut-point)
Number of subjects: 1781
Study 19843667 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 1781
Study 19843667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture II (hc2) testing
Number of subjects: 1781
Study 19843667 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a) ELISA (original version)
Number of subjects: 1781
Study 16618908 — intervention group
Group type: EXPERIMENTAL
Intervention: SELDI‐TOF‐MS assay
Number of subjects: 78
Study 14962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal prompts during task preparation
Number of subjects: 3
Study 14962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-compatible verbal prompts
Number of subjects: 3
Study 14962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-incompatible verbal prompts
Number of subjects: 3
Study 14962398 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-switching ability
Number of subjects: 3
Study 11343529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg daily for 12 weeks)
Number of subjects: 208
Study 11343529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 208
Study 11343529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 9392394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin injected immediately before breakfast
Number of subjects: 0
Study 9392394 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin injected 20 min preprandially
Number of subjects: 0
Study 7516978 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 3.75 mg depot injection every 28 days for 24 weeks
Number of subjects: 50
Study 7516978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2597713 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback from the forearm extensor and frontalis muscles
Number of subjects: 30
Study 2597713 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 30
Study 2597713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 2597713 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 30
Study 5667992 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 8
Study 30859848 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of vitamin C-enriched gelatin
Number of subjects: 10
Study 30859848 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of hydrolyzed collagen (HC)
Number of subjects: 10
Study 30859848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30859848 — intervention group
Group type: EXPERIMENTAL
Intervention: Gummy containing equal parts of gelatin and HC
Number of subjects: 10